Statin use and outcomes of oncological treatment for castration-resistant prostate cancer

Autor: A. I. Peltomaa, K. Talala, K. Taari, T. L. J. Tammela, A. Auvinen, T. J. Murtola

Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)

Abstract To compare the effect of statin use in relation to castration-resistant prostate cancer (CRPC) treatment, we assessed the risk of ADT-treated PCa-patients to initiate CRPC treatment by statin use and the outcomes of CRPC treatment by statin

Externí odkaz: https://doaj.org/article/1366b304409d469482ca76bea1f8b26a

Causal modeling to unravel the screening effect in ERSPC: Structural equation analysis of the Dutch, Finnish and Swedish data

Autor: S. Remmers, K. Talala, R. Arnsrud-Godtman, J. Hugosson, M.J. Roobol, D. Nieboer, A. Auvinen

Publikováno v: European Urology. 83:S1271-S1272

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e9ec4e4206f7e8de98bc31abf06e2dd
https://doi.org/10.1016/s0302-2838(23)00933-8

How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis

Autor: Aino Siltari, Ragnar Lönnerbro, Karl Pang, Kirill Shiranov, Alex Asiimwe, Susan Evans-Axelsson, Billy Franks, Amit Kiran, Teemu J. Murtola, Jack Schalken, Carl Steinbeisser, Anders Bjartell, Anssi Auvinen, J. N’Dow, E.J. Smith, R. Shepherd, M. Ribal, N. Mottet, L. Moris, M. Lardas, P-P. Willemse, G. Gandaglia, R. Campi, Rossella Nicoletti, M. Gacci, A. Briganti, M.M. Ratti, E. Alleva, L. Leardini, E.S. Sisca, R. Bangma, M. Roobol, S. Remmers, D. Tilki, T. Visakorpi, K. Talala, T. Tammela, M. van Hemelrijck, K. Bayer, S. Lejeune, S. Byrne, L. Fialho, P. Palaiologou B. De Meulder, C. Auffray, A. Hijazy, S. Power, N. Zounemat Kermani, K. van Bochove, M. Kalafati, M. Moinat, E. Voss, D. Horgan, L. Fullwood, M. Holtorf, D. Lancet, G. Bernstein, I. Omar, S. MacLennan, S. Maclennan, S. Tripathee, M. Wirth, M. Froehner, B. Brenner, A. Borkowetz, C. Thomas, F. Horn, K. Reiche, M. Kreux, A. Josefsson, D. Gasi Tandefekt, J. Hugosson, H. Huisman, J. Schalken, T. Hofmacher, P. Lindgren, E. Andersson, A. Fridhammar, J. Zong, J-E. Butler-Ransohoff, R. Herrera, M. Maass, P. Torremante, M.D. Voss, Z. Devecseri, T. Abbott, C. Dau, K. Papineni, R. Snijder, M. Lambrecht, R. Wolfinger, S. Rogiers, A. Servan, L. Antoni, K. Pacoe, P. Robinson, B. Jaton, D. Bakkard, H. Turunen, O. Kilkku, P. Pohjanjousi, O. Voima, L. Nevalaita, C. Reich, S. Araujo, E. Longden-Chapman, D. Burke, P. Agapow, S. Derkits, M. Licour, C. McCrea, S. Payne, A. Yong, L. Thompson, S. Le Mare, M Bussmann, D. Kotik

Publikováno v: Clinical Genitourinary Cancer, 21, 2, pp. 316.e1-316.e11
Clinical Genitourinary Cancer, 21, 316.e1-316.e11

Contains fulltext : 291547.pdf (Publisher’s version ) (Open Access) OBJECTIVES: Genome-wide association studies have revealed over 200 genetic susceptibility loci for prostate cancer (PCa). By combining them, polygenic risk scores (PRS) can be gene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aebe650dd619575ff9d0e1f7617b2c01
https://hdl.handle.net/2066/291547

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.